Pfizer’s Selzentry HIV Drug Faces India Opposition As Too Expensive (India)
This article was originally published in PharmAsia News
Executive SummaryPatient groups and two organizations are challenging the patent India gave to Pfizer for its Selzentry (maraviroc), one of a new class of oral AIDS drugs intended as second-line treatments. Medicines Sans frontiers and a Mumbai lawyer group are poring over the patent grant to see if it was justified, with an eye to questions raised about the drug by Europe's patent office. Challengers have a year from last June to mount an official challenge to granting a patent right. The U.S. FDA approved the drug in August. (Click here for more
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.